con il contributo non condizionante di:

SESSION I – EFFICACY SO FAR

Chairman: C.H. Moskowitz

Hodgkin lymphoma
C.H. Moskowitz
SESSION II – LECTURES ON HOT TOPICS

Chairman: P.L. Zinzani

SESSION III – NEXT STEPS: COMBINATIONS

Chairman: P. Armand

Nivolumab + AVD
S.M. Ansell
SESSION IV – NOVEL CHECKPOINT INHIBITORS

Chairman: B.D. Cheson

SESSION V – BISPECIFIC ANTIBODIES IN LYMPHOMAS

Chairman: C. Carlo-Stella

Mosunetuzumab
S. Assouline
Epcoritamab
M. Hutchings
Glofitamab
M. Hutchings
IGM-2323
E.L. Budde
SESSION VI – LECTURES ON HOT TOPICS

Chairman: G. Lenz

SESSION VII – CLINICAL DATA IN LARGE B-CELL LYMPHOMAS

Chairmen: P. Corradini, M. Ruella

Real-life data from US
C.A. Jacobson
Real-life data from US
L. Nastoupil
SESSION VIII – FUTURE INDICATIONS IN LARGE B-CELL LYPHOMAS

Chairmen: A.J.M. Ferreri, C. Tarella

Other anti-CD19
J.S. Abramson
ZUMA-12
S.S. Neelapu
SESSION IX – LECTURES ON HOT TOPICS

Chairman: F. Locatelli

Toxicity
S.S. Kenderian
SESSION X – OTHER LYMPHOMAS AND CLL

Chairman: N.H. Fowler

Hodgkin lymphoma
C.A. Ramos
Follicular lymphoma
N.H. Fowler
Follicular lymphoma
C.A. Jacobson
SESSION XI – THE NEXT STEPS...

C.A. Jacobson, S.J. Schuster